---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071514"
form_type: "8-K/A"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:24:32.127040+00:00"
event_type: "other"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics shareholders reject reverse stock split proposal at annual meeting

## Summary
- Reverse stock split proposal failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
- All four director nominees elected: Philippe Calais, Thomas Fitzgerald, Erik Manting, Magda Marquet.
- Stock plan amendment approved: 526,212 for, 205,773 against, 4,853 abstain.
- Auditor WithumSmith+Brown ratified: 2,193,452 for, 159,569 against, 39,556 abstain.
- Adjournment proposal passed but no adjournment motion made.

## SEC filing metadata
- accession: 0001104659-24-071514
- form_type: 8-K/A
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924071514/0001104659-24-071514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924071514/tm2417255d2_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071514
- JSON: https://secwatch.observer/filing/0001104659-24-071514.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.